Cardiogenic cerebral infarction: From prevention to acute treatment

Iwao Kuwajima, Takeshi Yamashita, Norihiro Suzuki, Shinya Goto, Jyoji Nakagawara

Research output: Contribution to journalArticle

Abstract

In Japan, the incidence of cardiogenic cerebral infarction caused by atrial fibrillation has been increasing rapidly. The major risk factor for the occurrence of cerebral infarction is age, but factors associated with the development of atrial fibrillation also play an important role, such as a history of cardiac failure, hypertension, diabetes, and cerebral infarction. Prophylactic therapy that inhibits the onset of atrial fibrillation itself, rather than symptomatic treatment after the onset of fibrillation, is important for the prevention of cardiogenic cerebral infarction. ARBs and renin-angiotensin receptor blockers are reported to be useful agents for prophylactic therapy. In addition to its antihypertensive effect, the ARB candesartan may suppress the development of atrial fibrillation. Large-scale clinical studies have shown that treatment with candesartan can prevent the occurrence of stroke. Management of high blood pressure is an essential part of the treatment of stroke, and it is particularly important in the acute phase when autoregulation of the cerebral circulation is impaired. Treatment with warfarin, as well as ARBs and statins (to improve endothelial function), is useful for preventing the recurrence of cardiogenic cerebral infarction. In particular, the ARB candesartan is very useful because of its additional protective effect on cognitive function.

Original languageEnglish
Pages (from-to)1169-1175
Number of pages7
JournalJapanese Pharmacology and Therapeutics
Volume33
Issue number12
Publication statusPublished - 2005

Fingerprint

Cerebral Infarction
Atrial Fibrillation
Cerebrovascular Circulation
Stroke
Hypertension
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Angiotensin Receptor Antagonists
Age Factors
Warfarin
Renin
Cognition
Antihypertensive Agents
Japan
Homeostasis
Heart Failure
Recurrence
Incidence
Therapeutics
candesartan

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Kuwajima, I., Yamashita, T., Suzuki, N., Goto, S., & Nakagawara, J. (2005). Cardiogenic cerebral infarction: From prevention to acute treatment. Japanese Pharmacology and Therapeutics, 33(12), 1169-1175.

Cardiogenic cerebral infarction : From prevention to acute treatment. / Kuwajima, Iwao; Yamashita, Takeshi; Suzuki, Norihiro; Goto, Shinya; Nakagawara, Jyoji.

In: Japanese Pharmacology and Therapeutics, Vol. 33, No. 12, 2005, p. 1169-1175.

Research output: Contribution to journalArticle

Kuwajima, I, Yamashita, T, Suzuki, N, Goto, S & Nakagawara, J 2005, 'Cardiogenic cerebral infarction: From prevention to acute treatment', Japanese Pharmacology and Therapeutics, vol. 33, no. 12, pp. 1169-1175.
Kuwajima I, Yamashita T, Suzuki N, Goto S, Nakagawara J. Cardiogenic cerebral infarction: From prevention to acute treatment. Japanese Pharmacology and Therapeutics. 2005;33(12):1169-1175.
Kuwajima, Iwao ; Yamashita, Takeshi ; Suzuki, Norihiro ; Goto, Shinya ; Nakagawara, Jyoji. / Cardiogenic cerebral infarction : From prevention to acute treatment. In: Japanese Pharmacology and Therapeutics. 2005 ; Vol. 33, No. 12. pp. 1169-1175.
@article{707b7481e4694a3c987e4acd7bd3e76e,
title = "Cardiogenic cerebral infarction: From prevention to acute treatment",
abstract = "In Japan, the incidence of cardiogenic cerebral infarction caused by atrial fibrillation has been increasing rapidly. The major risk factor for the occurrence of cerebral infarction is age, but factors associated with the development of atrial fibrillation also play an important role, such as a history of cardiac failure, hypertension, diabetes, and cerebral infarction. Prophylactic therapy that inhibits the onset of atrial fibrillation itself, rather than symptomatic treatment after the onset of fibrillation, is important for the prevention of cardiogenic cerebral infarction. ARBs and renin-angiotensin receptor blockers are reported to be useful agents for prophylactic therapy. In addition to its antihypertensive effect, the ARB candesartan may suppress the development of atrial fibrillation. Large-scale clinical studies have shown that treatment with candesartan can prevent the occurrence of stroke. Management of high blood pressure is an essential part of the treatment of stroke, and it is particularly important in the acute phase when autoregulation of the cerebral circulation is impaired. Treatment with warfarin, as well as ARBs and statins (to improve endothelial function), is useful for preventing the recurrence of cardiogenic cerebral infarction. In particular, the ARB candesartan is very useful because of its additional protective effect on cognitive function.",
author = "Iwao Kuwajima and Takeshi Yamashita and Norihiro Suzuki and Shinya Goto and Jyoji Nakagawara",
year = "2005",
language = "English",
volume = "33",
pages = "1169--1175",
journal = "Japanese Pharmacology and Therapeutics",
issn = "0386-3603",
publisher = "Life Science Publishing Co. Ltd",
number = "12",

}

TY - JOUR

T1 - Cardiogenic cerebral infarction

T2 - From prevention to acute treatment

AU - Kuwajima, Iwao

AU - Yamashita, Takeshi

AU - Suzuki, Norihiro

AU - Goto, Shinya

AU - Nakagawara, Jyoji

PY - 2005

Y1 - 2005

N2 - In Japan, the incidence of cardiogenic cerebral infarction caused by atrial fibrillation has been increasing rapidly. The major risk factor for the occurrence of cerebral infarction is age, but factors associated with the development of atrial fibrillation also play an important role, such as a history of cardiac failure, hypertension, diabetes, and cerebral infarction. Prophylactic therapy that inhibits the onset of atrial fibrillation itself, rather than symptomatic treatment after the onset of fibrillation, is important for the prevention of cardiogenic cerebral infarction. ARBs and renin-angiotensin receptor blockers are reported to be useful agents for prophylactic therapy. In addition to its antihypertensive effect, the ARB candesartan may suppress the development of atrial fibrillation. Large-scale clinical studies have shown that treatment with candesartan can prevent the occurrence of stroke. Management of high blood pressure is an essential part of the treatment of stroke, and it is particularly important in the acute phase when autoregulation of the cerebral circulation is impaired. Treatment with warfarin, as well as ARBs and statins (to improve endothelial function), is useful for preventing the recurrence of cardiogenic cerebral infarction. In particular, the ARB candesartan is very useful because of its additional protective effect on cognitive function.

AB - In Japan, the incidence of cardiogenic cerebral infarction caused by atrial fibrillation has been increasing rapidly. The major risk factor for the occurrence of cerebral infarction is age, but factors associated with the development of atrial fibrillation also play an important role, such as a history of cardiac failure, hypertension, diabetes, and cerebral infarction. Prophylactic therapy that inhibits the onset of atrial fibrillation itself, rather than symptomatic treatment after the onset of fibrillation, is important for the prevention of cardiogenic cerebral infarction. ARBs and renin-angiotensin receptor blockers are reported to be useful agents for prophylactic therapy. In addition to its antihypertensive effect, the ARB candesartan may suppress the development of atrial fibrillation. Large-scale clinical studies have shown that treatment with candesartan can prevent the occurrence of stroke. Management of high blood pressure is an essential part of the treatment of stroke, and it is particularly important in the acute phase when autoregulation of the cerebral circulation is impaired. Treatment with warfarin, as well as ARBs and statins (to improve endothelial function), is useful for preventing the recurrence of cardiogenic cerebral infarction. In particular, the ARB candesartan is very useful because of its additional protective effect on cognitive function.

UR - http://www.scopus.com/inward/record.url?scp=32844461773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32844461773&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:32844461773

VL - 33

SP - 1169

EP - 1175

JO - Japanese Pharmacology and Therapeutics

JF - Japanese Pharmacology and Therapeutics

SN - 0386-3603

IS - 12

ER -